News
INDIANAPOLIS, June 26, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) trial studying higher investigational doses of Trulicity ® (dulaglutide) met its primary efficacy endpoint of ...
The win puts Trulicity in a small group of GLP-1 drugs that have posted heart-helping benefits for patients. The thing is, Novo Nordisk’s weekly Ozempic—whose active ingredient, semaglutide ...
This decision makes Eli Lilly and Company's (NYSE: LLY) Trulicity the first and only type 2 diabetes medicine approved to reduce the risk of MACE for both primary and secondary prevention populations.
Shares of Eli Lilly & Co. fell 2.4% in premarket trade on Monday after a randomized control trial showed that diabetes drug Trulicity lowered the risk of major cardiovascular events in patients ...
Only 31 percent of those in the 9,901-patient study had heart disease, the company said. The trial compared 1.5 milligrams of Trulicity once a week to placebo, with the primary goal a reduction in ...
Lilly expands Trulicity marketing push, lowers 2015 guidance . The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results